TY - JOUR AU - Ledford, H. PY - 2011 DA - 2011// TI - Melanoma drug wins US approval JO - Nature VL - 471 UR - https://doi.org/10.1038/471561a DO - 10.1038/471561a ID - Ledford2011 ER - TY - JOUR AU - Pardoll, D. M. PY - 2012 DA - 2012// TI - The blockade of immune checkpoints in cancer immunotherapy JO - Nat Rev Cancer VL - 12 UR - https://doi.org/10.1038/nrc3239 DO - 10.1038/nrc3239 ID - Pardoll2012 ER - TY - JOUR AU - Vinay, D. S. AU - Ryan, E. P. AU - Pawelec, G. PY - 2015 DA - 2015// TI - Immune evasion in cancer: mechanistic basis and therapeutic strategies JO - Semin Cancer Biol VL - 35 UR - https://doi.org/10.1016/j.semcancer.2015.03.004 DO - 10.1016/j.semcancer.2015.03.004 ID - Vinay2015 ER - TY - JOUR AU - Whiteside, T. L. PY - 2008 DA - 2008// TI - The tumor microenvironment and its role in promoting tumor growth JO - Oncogene VL - 27 UR - https://doi.org/10.1038/onc.2008.271 DO - 10.1038/onc.2008.271 ID - Whiteside2008 ER - TY - JOUR AU - Chen, L. AU - Flies, D. B. PY - 2013 DA - 2013// TI - Molecular mechanisms of T cell co-stimulation and co-inhibition JO - Nat Rev Immunol VL - 13 UR - https://doi.org/10.1038/nri3405 DO - 10.1038/nri3405 ID - Chen2013 ER - TY - JOUR AU - Wei, S. C. AU - Duffy, C. R. AU - Allison, J. P. PY - 2018 DA - 2018// TI - Fundamental mechanisms of immune checkpoint blockade therapy JO - Cancer Discov VL - 8 UR - https://doi.org/10.1158/2159-8290.CD-18-0367 DO - 10.1158/2159-8290.CD-18-0367 ID - Wei2018 ER - TY - JOUR AU - Seidel, J. A. AU - Otsuka, A. AU - Kabashima, K. PY - 2018 DA - 2018// TI - Anti-PD-1 and Anti-CTLA-4 therapies in cancer: mechanisms of action, efficacy, and limitations JO - Front Oncol VL - 8 UR - https://doi.org/10.3389/fonc.2018.00086 DO - 10.3389/fonc.2018.00086 ID - Seidel2018 ER - TY - JOUR AU - Robert, C. PY - 2020 DA - 2020// TI - A decade of immune-checkpoint inhibitors in cancer therapy JO - Nat Commun VL - 11 UR - https://doi.org/10.1038/s41467-020-17670-y DO - 10.1038/s41467-020-17670-y ID - Robert2020 ER - TY - JOUR AU - Darvin, P. AU - Toor, S. M. AU - Sasidharan Nair, V. AU - Elkord, E. PY - 2018 DA - 2018// TI - Immune checkpoint inhibitors: recent progress and potential biomarkers JO - Exp Mol Med VL - 50 UR - https://doi.org/10.1038/s12276-018-0191-1 DO - 10.1038/s12276-018-0191-1 ID - Darvin2018 ER - TY - JOUR AU - Marin-Acevedo, J. A. AU - Chirila, R. M. AU - Dronca, R. S. PY - 2019 DA - 2019// TI - Immune checkpoint inhibitor toxicities JO - Mayo Clin Proc VL - 94 UR - https://doi.org/10.1016/j.mayocp.2019.03.012 DO - 10.1016/j.mayocp.2019.03.012 ID - Marin-Acevedo2019 ER - TY - JOUR AU - Postow, M. A. AU - Sidlow, R. AU - Hellmann, M. D. PY - 2018 DA - 2018// TI - Immune-related adverse events associated with immune checkpoint blockade JO - New Engl J Med VL - 378 UR - https://doi.org/10.1056/NEJMra1703481 DO - 10.1056/NEJMra1703481 ID - Postow2018 ER - TY - JOUR AU - Granier, C. AU - Guillebon, E. AU - Blanc, C. PY - 2017 DA - 2017// TI - Mechanisms of action and rationale for the use of checkpoint inhibitors in cancer JO - Esmo Open. VL - 2 UR - https://doi.org/10.1136/esmoopen-2017-000213 DO - 10.1136/esmoopen-2017-000213 ID - Granier2017 ER - TY - JOUR AU - Marin-Acevedo, J. A. AU - Dholaria, B. AU - Soyano, A. E. AU - Knutson, K. L. AU - Chumsri, S. AU - Lou, Y. PY - 2018 DA - 2018// TI - Next generation of immune checkpoint therapy in cancer: new developments and challenges JO - J Hematol Oncol VL - 11 UR - https://doi.org/10.1186/s13045-018-0582-8 DO - 10.1186/s13045-018-0582-8 ID - Marin-Acevedo2018 ER - TY - JOUR AU - Buchbinder, E. I. AU - Desai, A. PY - 2016 DA - 2016// TI - CTLA-4 and PD-1 pathways: similarities, differences, and implications of their inhibition JO - Am J Clin Oncol VL - 39 UR - https://doi.org/10.1097/COC.0000000000000239 DO - 10.1097/COC.0000000000000239 ID - Buchbinder2016 ER - TY - JOUR AU - Sharma, P. AU - Allison, J. P. PY - 2015 DA - 2015// TI - The future of immune checkpoint therapy JO - Science VL - 348 UR - https://doi.org/10.1126/science.aaa8172 DO - 10.1126/science.aaa8172 ID - Sharma2015 ER - TY - JOUR AU - Andrews, L. P. AU - Yano, H. AU - Vignali, D. A. A. PY - 2019 DA - 2019// TI - Inhibitory receptors and ligands beyond PD-1, PD-L1 and CTLA-4: breakthroughs or backups JO - Nat Immunol VL - 20 UR - https://doi.org/10.1038/s41590-019-0512-0 DO - 10.1038/s41590-019-0512-0 ID - Andrews2019 ER - TY - JOUR AU - Goldberg, M. V. AU - Drake, C. G. PY - 2011 DA - 2011// TI - LAG-3 in cancer immunotherapy JO - Curr Top Microbiol Immunol VL - 344 ID - Goldberg2011 ER - TY - JOUR AU - Anderson, A. C. AU - Joller, N. AU - Kuchroo, V. K. PY - 2016 DA - 2016// TI - Lag-3, Tim-3, and TIGIT: co-inhibitory receptors with specialized functions in immune regulation JO - Immunity VL - 44 UR - https://doi.org/10.1016/j.immuni.2016.05.001 DO - 10.1016/j.immuni.2016.05.001 ID - Anderson2016 ER - TY - JOUR AU - Andrews, L. P. AU - Marciscano, A. E. AU - Drake, C. G. AU - Vignali, D. A. A. PY - 2017 DA - 2017// TI - LAG3 (CD223) as a cancer immunotherapy target JO - Immunol Rev VL - 276 UR - https://doi.org/10.1111/imr.12519 DO - 10.1111/imr.12519 ID - Andrews2017 ER - TY - JOUR AU - Hong, D. S. AU - Schoffski, P. AU - Calvo, A. PY - 2018 DA - 2018// TI - Phase I/II study of LAG525 ± spartalizumab (PDR001) in patients (pts) with advanced malignancies JO - J Clin Oncol VL - 36 UR - https://doi.org/10.1200/JCO.2018.36.15_suppl.3012 DO - 10.1200/JCO.2018.36.15_suppl.3012 ID - Hong2018 ER - TY - JOUR AU - Uboha, N. V. AU - Milhem, M. M. AU - Kovacs, C. PY - 2019 DA - 2019// TI - Phase II study of spartalizumab (PDR001) and LAG525 in advanced solid tumors and hematologic malignancies JO - J Clin Oncol VL - 37 UR - https://doi.org/10.1200/JCO.2019.37.15_suppl.2553 DO - 10.1200/JCO.2019.37.15_suppl.2553 ID - Uboha2019 ER - TY - JOUR AU - Papadopoulos, K. P. AU - Lakhani, N. J. AU - Johnson, M. L. PY - 2019 DA - 2019// TI - First-in-human study of REGN3767 (R3767), a human LAG-3 monoclonal antibody (mAb), ± cemiplimab in patients (pts) with advanced malignancies JO - J Clin Oncol VL - 37 UR - https://doi.org/10.1200/JCO.2019.37.15_suppl.2508 DO - 10.1200/JCO.2019.37.15_suppl.2508 ID - Papadopoulos2019 ER - TY - JOUR AU - Johnson, M. L. AU - Patel, M. R. AU - Cherry, M. PY - 2020 DA - 2020// TI - Safety of BI 754111, an anti-LAG-3 monoclonal antibody (mAb), in combination with BI 754091, an anti-PD-1 mAb, in patients with advanced solid tumors JO - J Clin Oncol VL - 38 UR - https://doi.org/10.1200/JCO.2020.38.15_suppl.3063 DO - 10.1200/JCO.2020.38.15_suppl.3063 ID - Johnson2020 ER - TY - JOUR AU - Luke, J. J. AU - Patel, M. R. AU - Hamilton, E. P. PY - 2020 DA - 2020// TI - A phase I, first-in-human, open-label, dose-escalation study of MGD013, a bispecific DART molecule binding PD-1 and LAG-3, in patients with unresectable or metastatic neoplasms JO - J Clin Oncol VL - 38 UR - https://doi.org/10.1200/JCO.2020.38.15_suppl.3004 DO - 10.1200/JCO.2020.38.15_suppl.3004 ID - Luke2020 ER - TY - JOUR AU - Eastgate, M. A. AU - Atkinson, V. AU - Khattak, M. A. PY - 2018 DA - 2018// TI - Pushing the accelerator and releasing the brake: a phase I dose escalation study evaluating a LAG-3 fusion protein (eftilagimod alpha), together with pembrolizumab in unresectable or metastatic melanoma JO - J Clin Oncol VL - 36 UR - https://doi.org/10.1200/JCO.2018.36.15_suppl.e15099 DO - 10.1200/JCO.2018.36.15_suppl.e15099 ID - Eastgate2018 ER - TY - JOUR AU - Goetze, T. O. AU - Mueller, D. W. AU - Rafiyan, M. -. R. PY - 2020 DA - 2020// TI - Open-label, phase I study evaluating feasibility and safety of subcutaneous IMP321 (LAG-3Ig fusion protein, eftilagimod alpha) combined with avelumab in advanced stage solid tumor entities: results from stratum D of the INSIGHT platform trial JO - J Clin Oncol VL - 38 UR - https://doi.org/10.1200/JCO.2020.38.15_suppl.3099 DO - 10.1200/JCO.2020.38.15_suppl.3099 ID - Goetze2020 ER - TY - JOUR AU - Felip, E. AU - Doger, B. AU - Majem, M. PY - 2020 DA - 2020// TI - Initial results from a phase II study (TACTI-002) in metastatic non-small cell lung or head and neck carcinoma patients receiving eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab JO - J Clin Oncol VL - 38 UR - https://doi.org/10.1200/JCO.2020.38.15_suppl.3100 DO - 10.1200/JCO.2020.38.15_suppl.3100 ID - Felip2020 ER - TY - JOUR AU - He, Y. AU - Cao, J. AU - Zhao, C. AU - Li, X. AU - Zhou, C. AU - Hirsch, F. R. PY - 2018 DA - 2018// TI - TIM-3, a promising target for cancer immunotherapy JO - Oncol Targets Ther VL - 11 UR - https://doi.org/10.2147/OTT.S170385 DO - 10.2147/OTT.S170385 ID - He2018 ER - TY - JOUR AU - Das, M. AU - Zhu, C. AU - Kuchroo, V. K. PY - 2017 DA - 2017// TI - Tim-3 and its role in regulating anti-tumor immunity JO - Immunol Rev VL - 276 UR - https://doi.org/10.1111/imr.12520 DO - 10.1111/imr.12520 ID - Das2017 ER - TY - JOUR AU - Du, W. AU - Yang, M. AU - Turner, A. PY - 2017 DA - 2017// TI - TIM-3 as a target for cancer immunotherapy and mechanisms of action JO - Int J Mol Sci VL - 18 UR - https://doi.org/10.3390/ijms18030645 DO - 10.3390/ijms18030645 ID - Du2017 ER - TY - JOUR AU - Curigliano, G. AU - Gelderblom, H. AU - Mach, N. PY - 2019 DA - 2019// TI - Abstract CT183: phase (Ph) I/II study of MBG453± spartalizumab (PDR001) in patients (pts) with advanced malignancies JO - Cancer Res VL - 79 UR - https://doi.org/10.1158/1538-7445.AM2019-CT183 DO - 10.1158/1538-7445.AM2019-CT183 ID - Curigliano2019 ER - TY - JOUR AU - Picarda, E. AU - Ohaegbulam, K. C. AU - Zang, X. X. PY - 2016 DA - 2016// TI - Molecular pathways: targeting B7–H3 (CD276) for human cancer immunotherapy JO - Clin Cancer Res VL - 22 UR - https://doi.org/10.1158/1078-0432.CCR-15-2428 DO - 10.1158/1078-0432.CCR-15-2428 ID - Picarda2016 ER - TY - JOUR AU - Yang, S. AU - Wei, W. AU - Zhao, Q. PY - 2020 DA - 2020// TI - B7–H3, a checkpoint molecule, as a target for cancer immunotherapy JO - Int J Biol Sci VL - 16 UR - https://doi.org/10.7150/ijbs.41105 DO - 10.7150/ijbs.41105 ID - Yang2020 ER - TY - JOUR AU - Podojil, J. R. AU - Miller, S. D. PY - 2017 DA - 2017// TI - Potential targeting of B7–H4 for the treatment of cancer JO - Immunol Rev VL - 276 UR - https://doi.org/10.1111/imr.12530 DO - 10.1111/imr.12530 ID - Podojil2017 ER - TY - JOUR AU - Powderly, J. D. AU - Jang, S. AU - Lohr, J. AU - Spira, A. I. AU - Bohac, G. C. AU - Sharma, M. PY - 2020 DA - 2020// TI - Preliminary dose escalation results from a phase I/II, first-in-human study of MGC018 (anti-B7-H3 antibody-drug conjugate) in patients with advanced solid tumors JO - J Clin Oncol VL - 38 UR - https://doi.org/10.1200/JCO.2020.38.15_suppl.3071 DO - 10.1200/JCO.2020.38.15_suppl.3071 ID - Powderly2020 ER - TY - JOUR AU - Sachdev, J. C. AU - Bauer, T. M. AU - Chawla, S. P. PY - 2019 DA - 2019// TI - Phase 1a/1b study of first-in-class B7–H4 antibody, FPA150, as monotherapy in patients with advanced solid tumors JO - J Clin Oncol VL - 37 UR - https://doi.org/10.1200/JCO.2019.37.15_suppl.2529 DO - 10.1200/JCO.2019.37.15_suppl.2529 ID - Sachdev2019 ER - TY - JOUR AU - Vigano, S. AU - Alatzoglou, D. AU - Irving, M. PY - 2019 DA - 2019// TI - Targeting adenosine in cancer immunotherapy to enhance T-cell function JO - Front Immunol VL - 10 UR - https://doi.org/10.3389/fimmu.2019.00925 DO - 10.3389/fimmu.2019.00925 ID - Vigano2019 ER - TY - JOUR AU - Leone, R. D. AU - Lo, Y. C. AU - Powell, J. D. PY - 2015 DA - 2015// TI - A2aR antagonists: next generation checkpoint blockade for cancer immunotherapy JO - Comput Struct Biotechnol J VL - 13 UR - https://doi.org/10.1016/j.csbj.2015.03.008 DO - 10.1016/j.csbj.2015.03.008 ID - Leone2015 ER - TY - JOUR AU - Jiang, T. AU - Xu, X. AU - Qiao, M. PY - 2018 DA - 2018// TI - Comprehensive evaluation of NT5E/CD73 expression and its prognostic significance in distinct types of cancers JO - BMC Cancer VL - 18 UR - https://doi.org/10.1186/s12885-018-4073-7 DO - 10.1186/s12885-018-4073-7 ID - Jiang2018 ER - TY - JOUR AU - Vijayan, D. AU - Young, A. AU - Teng, M. W. L. AU - Smyth, M. J. PY - 2017 DA - 2017// TI - Targeting immunosuppressive adenosine in cancer (vol 17, pg 709, 2017) JO - Nat Rev Cancer VL - 17 ID - Vijayan2017 ER - TY - JOUR AU - Buisseret, L. AU - Rottey, S. AU - Bono, J. PY - 2020 DA - 2020// TI - Abstract CT152: first in human study with EOS100850, a novel potent A2A antagonist, shows excellent tolerance and clinical benefit in immune resistant advanced cancers JO - Cancer Res VL - 80 UR - https://doi.org/10.1158/1538-7445.AM2020-CT152 DO - 10.1158/1538-7445.AM2020-CT152 ID - Buisseret2020 ER - TY - JOUR AU - Powderly, J. D. AU - Souza, P. L. AU - Gutierrez, R. PY - 2019 DA - 2019// TI - AB928, a novel dual adenosine receptor antagonist, combined with chemotherapy or AB122 (anti-PD-1) in patients (pts) with advanced tumors: preliminary results from ongoing phase I studies JO - J Clin Oncol VL - 37 UR - https://doi.org/10.1200/JCO.2019.37.15_suppl.2604 DO - 10.1200/JCO.2019.37.15_suppl.2604 ID - Powderly2019 ER - TY - JOUR AU - Luke, J. J. AU - Powderly, J. D. AU - Merchan, J. R. PY - 2019 DA - 2019// TI - Immunobiology, preliminary safety, and efficacy of CPI-006, an anti-CD73 antibody with immune modulating activity, in a phase 1 trial in advanced cancers JO - J Clin Oncol VL - 37 UR - https://doi.org/10.1200/JCO.2019.37.15_suppl.2505 DO - 10.1200/JCO.2019.37.15_suppl.2505 ID - Luke2019 ER - TY - JOUR AU - Andre, P. AU - Denis, C. AU - Soulas, C. PY - 2018 DA - 2018// TI - Anti-NKG2A mAb Is a checkpoint inhibitor that promotes anti-tumor immunity by unleashing both T and NK cells JO - Cell VL - 175 UR - https://doi.org/10.1016/j.cell.2018.10.014 DO - 10.1016/j.cell.2018.10.014 ID - Andre2018 ER - TY - JOUR AU - Creelan, B. C. AU - Antonia, S. J. PY - 2019 DA - 2019// TI - The NKG2A immune checkpoint—a new direction in cancer immunotherapy JO - Nat Rev Clin Oncol VL - 16 UR - https://doi.org/10.1038/s41571-019-0182-8 DO - 10.1038/s41571-019-0182-8 ID - Creelan2019 ER - TY - JOUR AU - Bastidas-Legarda, L. Y. AU - Khakoo, S. I. PY - 2019 DA - 2019// TI - Conserved and variable natural killer cell receptors: diverse approaches to viral infections JO - Immunology VL - 156 UR - https://doi.org/10.1111/imm.13039 DO - 10.1111/imm.13039 ID - Bastidas-Legarda2019 ER - TY - JOUR AU - Hellmann, M. D. AU - Snyder, A. PY - 2019 DA - 2019// TI - Adding to the checkpoint blockade armamentarium JO - Nat Med VL - 25 UR - https://doi.org/10.1038/s41591-019-0350-5 DO - 10.1038/s41591-019-0350-5 ID - Hellmann2019 ER - TY - JOUR AU - Galot, R. AU - Tourneau, C. AU - Saada-Bouzid, E. PY - 2019 DA - 2019// TI - 1109O—a phase II study of monalizumab in patients with recurrent/metastatic (RM) squamous cell carcinoma of the head and neck (SCCHN): results of the I1 cohort of the EORTC-HNCG-1559 trial (UPSTREAM) JO - Ann Oncol VL - 30 UR - https://doi.org/10.1093/annonc/mdz252.001 DO - 10.1093/annonc/mdz252.001 ID - Galot2019 ER - TY - JOUR AU - Cohen, R. B. AU - Bauman, J. R. AU - Salas, S. PY - 2020 DA - 2020// TI - Combination of monalizumab and cetuximab in recurrent or metastatic head and neck cancer patients previously treated with platinum-based chemotherapy and PD-(L)1 inhibitors JO - J Clin Oncol VL - 38 UR - https://doi.org/10.1200/JCO.2020.38.15_suppl.6516 DO - 10.1200/JCO.2020.38.15_suppl.6516 ID - Cohen2020 ER - TY - JOUR AU - Cohen, R. AU - Fayette, J. AU - Posner, M. PY - 2018 DA - 2018// TI - Abstract CT158: phase II study of monalizumab, a first-in-class NKG2A monoclonal antibody, in combination with cetuximab in previously treated recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): Preliminary assessment of safety and efficacy JO - Cancer Res VL - 78 UR - https://doi.org/10.1158/1538-7445.AM2018-CT158 DO - 10.1158/1538-7445.AM2018-CT158 ID - Cohen2018 ER - TY - JOUR AU - Zhu, Y. AU - Paniccia, A. AU - Schulick, A. C. PY - 2016 DA - 2016// TI - Identification of CD112R as a novel checkpoint for human T cells JO - J Exp Med VL - 213 UR - https://doi.org/10.1084/jem.20150785 DO - 10.1084/jem.20150785 ID - Zhu2016 ER - TY - JOUR AU - Whelan, S. AU - Ophir, E. AU - Kotturi, M. F. PY - 2019 DA - 2019// TI - PVRIG and PVRL2 are induced in cancer and inhibit CD8(+) T-cell function JO - Cancer Immunol Res VL - 7 UR - https://doi.org/10.1158/2326-6066.CIR-18-0442 DO - 10.1158/2326-6066.CIR-18-0442 ID - Whelan2019 ER - TY - JOUR AU - Sullivan, R. AU - Rasco, D. AU - Lim, E. PY - 2020 DA - 2020// TI - Abstract CT031: COM701 demonstrates preliminary antitumor activity as monotherapy and in combination with nivolumab in patients with advanced solid tumors JO - Cancer Res VL - 80 UR - https://doi.org/10.1158/1538-7445.AM2020-CT031 DO - 10.1158/1538-7445.AM2020-CT031 ID - Sullivan2020 ER - TY - JOUR AU - Rizeq, B. AU - Zakaria, Z. AU - Ouhtit, A. PY - 2018 DA - 2018// TI - Towards understanding the mechanisms of actions of carcinoembryonic antigen-related cell adhesion molecule 6 in cancer progression JO - Cancer Sci VL - 109 UR - https://doi.org/10.1111/cas.13437 DO - 10.1111/cas.13437 ID - Rizeq2018 ER - TY - JOUR AU - Dankner, M. AU - Gray-Owen, S. D. AU - Huang, Y. H. AU - Blumberg, R. S. AU - Beauchemin, N. PY - 2017 DA - 2017// TI - CEACAM1 as a multi-purpose target for cancer immunotherapy JO - Oncoimmunology VL - 6 ID - Dankner2017 ER - TY - JOUR AU - Johnson, B. AU - Mahadevan, D. PY - 2015 DA - 2015// TI - Emerging role and targeting of carcinoembryonic antigen-related cell adhesion molecule 6 (CEACAM6) in human malignancies JO - Clin Cancer Drugs VL - 2 UR - https://doi.org/10.2174/2212697X02666150602215823 DO - 10.2174/2212697X02666150602215823 ID - Johnson2015 ER - TY - JOUR AU - Calinescu, A. AU - Turcu, G. AU - Nedelcu, R. I. PY - 2018 DA - 2018// TI - On the dual role of carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1) in human malignancies JO - J Immunol Res VL - 2018 UR - https://doi.org/10.1155/2018/7169081 DO - 10.1155/2018/7169081 ID - Calinescu2018 ER - TY - JOUR AU - Skubitz, K. M. AU - Campbell, K. D. AU - Skubitz, A. P. PY - 1996 DA - 1996// TI - CD66a, CD66b, CD66c, and CD66d each independently stimulate neutrophils JO - J Leukoc Biol VL - 60 UR - https://doi.org/10.1002/jlb.60.1.106 DO - 10.1002/jlb.60.1.106 ID - Skubitz1996 ER - TY - JOUR AU - Shapira, R. AU - Weber, J. S. AU - Geva, R. PY - 2020 DA - 2020// TI - A phase I, open-label, multicenter, single-dose escalation and multi-dose study of a monoclonal antibody targeting CEACAM1 in subjects with selected advanced or recurrent malignancies JO - J Clin Oncol VL - 38 UR - https://doi.org/10.1200/JCO.2020.38.15_suppl.3094 DO - 10.1200/JCO.2020.38.15_suppl.3094 ID - Shapira2020 ER - TY - JOUR AU - Morelli, M. P. AU - Fantini, M. AU - Houston, N. D. PY - 2020 DA - 2020// TI - Correlation of clinical activity of NEO201 mAb with the expression of NK activation markers and levels of soluble factors JO - J Clin Oncol VL - 38 UR - https://doi.org/10.1200/JCO.2020.38.15_suppl.e15002 DO - 10.1200/JCO.2020.38.15_suppl.e15002 ID - Morelli2020 ER - TY - JOUR AU - Morelli, M. P. AU - Houston, N. D. AU - Lipkowitz, S. PY - 2020 DA - 2020// TI - Phase I with expansion cohorts in a study of NEO-201 in adults with chemo-resistant solid tumors JO - J Clin Oncol VL - 38 UR - https://doi.org/10.1200/JCO.2020.38.4_suppl.129 DO - 10.1200/JCO.2020.38.4_suppl.129 ID - Morelli2020 ER - TY - JOUR AU - Wang-Gillam, A. AU - McWilliams, R. AU - Lockhart, A. C. PY - 2020 DA - 2020// TI - Abstract CT118: phase I study of defactinib combined with pembrolizumab and gemcitabine in patients with advanced cancer: experiences of pancreatic ductal adenocarcinoma (PDAC) patients JO - Cancer Res VL - 80 UR - https://doi.org/10.1158/1538-7445.AM2020-CT118 DO - 10.1158/1538-7445.AM2020-CT118 ID - Wang-Gillam2020 ER - TY - JOUR AU - Griffith, J. W. AU - Sokol, C. L. AU - Luster, A. D. PY - 2014 DA - 2014// TI - Chemokines and chemokine receptors: positioning cells for host defense and immunity JO - Annu Rev Immunol VL - 32 UR - https://doi.org/10.1146/annurev-immunol-032713-120145 DO - 10.1146/annurev-immunol-032713-120145 ID - Griffith2014 ER - TY - JOUR AU - Mollica Poeta, V. AU - Massara, M. AU - Capucetti, A. AU - Bonecchi, R. PY - 2019 DA - 2019// TI - Chemokines and chemokine receptors: new targets for cancer immunotherapy JO - Front Immunol VL - 10 UR - https://doi.org/10.3389/fimmu.2019.00379 DO - 10.3389/fimmu.2019.00379 ID - Mollica Poeta2019 ER - TY - JOUR AU - Hao, Q. AU - Vadgama, J. V. AU - Wang, P. PY - 2020 DA - 2020// TI - CCL2/CCR2 signaling in cancer pathogenesis JO - Cell Commun Signal VL - 18 UR - https://doi.org/10.1186/s12964-020-00589-8 DO - 10.1186/s12964-020-00589-8 ID - Hao2020 ER - TY - JOUR AU - Fridlender, Z. G. AU - Buchlis, G. AU - Kapoor, V. PY - 2010 DA - 2010// TI - CCL2 blockade augments cancer immunotherapy JO - Cancer Res VL - 70 UR - https://doi.org/10.1158/0008-5472.CAN-09-2326 DO - 10.1158/0008-5472.CAN-09-2326 ID - Fridlender2010 ER - TY - JOUR AU - Loyher, P. L. AU - Rochefort, J. AU - Baudesson de Chanville, C. PY - 2016 DA - 2016// TI - CCR2 influences T regulatory cell migration to tumors and serves as a biomarker of cyclophosphamide sensitivity JO - Cancer Res. VL - 76 UR - https://doi.org/10.1158/0008-5472.CAN-16-0984 DO - 10.1158/0008-5472.CAN-16-0984 ID - Loyher2016 ER - TY - JOUR AU - Gschwandtner, M. AU - Derler, R. AU - Midwood, K. S. PY - 2019 DA - 2019// TI - More than just attractive: how CCL2 influences myeloid cell behavior beyond chemotaxis JO - Front Immunol VL - 10 UR - https://doi.org/10.3389/fimmu.2019.02759 DO - 10.3389/fimmu.2019.02759 ID - Gschwandtner2019 ER - TY - JOUR AU - Noel, M. AU - O'Reilly, E. M. AU - Wolpin, B. M. PY - 2020 DA - 2020// TI - Phase 1b study of a small molecule antagonist of human chemokine (C–C motif) receptor 2 (PF-04136309) in combination with nab-paclitaxel/gemcitabine in first-line treatment of metastatic pancreatic ductal adenocarcinoma JO - Invest New Drugs VL - 38 UR - https://doi.org/10.1007/s10637-019-00830-3 DO - 10.1007/s10637-019-00830-3 ID - Noel2020 ER - TY - JOUR AU - Pascual-Garcia, M. AU - Bonfill-Teixidor, E. AU - Planas-Rigol, E. PY - 2019 DA - 2019// TI - LIF regulates CXCL9 in tumor-associated macrophages and prevents CD8(+) T cell tumor-infiltration impairing anti-PD1 therapy JO - Nat Commun VL - 10 UR - https://doi.org/10.1038/s41467-019-10369-9 DO - 10.1038/s41467-019-10369-9 ID - Pascual-Garcia2019 ER - TY - JOUR AU - Novotny, Z. AU - Krizan, J. AU - Sima, R. PY - 2009 DA - 2009// TI - Leukaemia inhibitory factor (LIF) gene mutations in women diagnosed with unexplained infertility and endometriosis have a negative impact on the IVF outcome. A pilot study JO - Folia Biol (Praha) VL - 55 ID - Novotny2009 ER - TY - JOUR AU - Stewart, C. L. AU - Kaspar, P. AU - Brunet, L. J. PY - 1992 DA - 1992// TI - Blastocyst implantation depends on maternal expression of leukaemia inhibitory factor JO - Nature VL - 359 UR - https://doi.org/10.1038/359076a0 DO - 10.1038/359076a0 ID - Stewart1992 ER - TY - JOUR AU - Schram, A. AU - Borazanci, E. AU - Brana, I. PY - 2020 DA - 2020// TI - Abstract CT147: Phase 1 dose escalation of MSC-1, a humanized anti-LIF monoclonal antibody, in patients with advanced solid tumors JO - Cancer Res VL - 80 UR - https://doi.org/10.1158/1538-7445.AM2020-CT147 DO - 10.1158/1538-7445.AM2020-CT147 ID - Schram2020 ER - TY - JOUR AU - Weiskopf, K. PY - 2017 DA - 2017// TI - Cancer immunotherapy targeting the CD47/SIRPα axis JO - Eur J Cancer VL - 76 UR - https://doi.org/10.1016/j.ejca.2017.02.013 DO - 10.1016/j.ejca.2017.02.013 ID - Weiskopf2017 ER - TY - JOUR AU - Tong, B. AU - Wang, M. Z. PY - 2018 DA - 2018// TI - CD47 is a novel potent immunotherapy target in human malignancies: current studies and future promises JO - Future Oncol VL - 14 UR - https://doi.org/10.2217/fon-2018-0035 DO - 10.2217/fon-2018-0035 ID - Tong2018 ER - TY - JOUR AU - Sudo, T. AU - Takahashi, Y. AU - Sawada, G. AU - Uchi, R. AU - Mimori, K. AU - Akagi, Y. PY - 2017 DA - 2017// TI - Significance of CD47 expression in gastric cancer JO - Oncol Lett VL - 14 UR - https://doi.org/10.3892/ol.2017.6257 DO - 10.3892/ol.2017.6257 ID - Sudo2017 ER - TY - JOUR AU - Xiao, Z. AU - Chung, H. AU - Banan, B. PY - 2015 DA - 2015// TI - Antibody mediated therapy targeting CD47 inhibits tumor progression of hepatocellular carcinoma JO - Cancer Lett VL - 360 UR - https://doi.org/10.1016/j.canlet.2015.02.036 DO - 10.1016/j.canlet.2015.02.036 ID - Xiao2015 ER - TY - JOUR AU - Weiskopf, K. AU - Jahchan, N. S. AU - Schnorr, P. J. PY - 2016 DA - 2016// TI - CD47-blocking immunotherapies stimulate macrophage-mediated destruction of small-cell lung cancer JO - J Clin Invest VL - 126 UR - https://doi.org/10.1172/JCI81603 DO - 10.1172/JCI81603 ID - Weiskopf2016 ER - TY - JOUR AU - Kaur, S. AU - Elkahloun, A. G. AU - Singh, S. P. PY - 2016 DA - 2016// TI - A function-blocking CD47 antibody suppresses stem cell and EGF signaling in triple-negative breast cancer JO - Oncotarget VL - 7 UR - https://doi.org/10.18632/oncotarget.7100 DO - 10.18632/oncotarget.7100 ID - Kaur2016 ER - TY - JOUR AU - Schupp, J. AU - Krebs, F. K. AU - Zimmer, N. AU - Trzeciak, E. AU - Schuppan, D. AU - Tuettenberg, A. PY - 2017 DA - 2017// TI - Targeting myeloid cells in the tumor sustaining microenvironment JO - Cell Immunol. VL - 343 UR - https://doi.org/10.1016/j.cellimm.2017.10.013 DO - 10.1016/j.cellimm.2017.10.013 ID - Schupp2017 ER - TY - JOUR AU - Murata, Y. AU - Saito, Y. AU - Kotani, T. AU - Matozaki, T. PY - 2018 DA - 2018// TI - CD47-signal regulatory protein alpha signaling system and its application to cancer immunotherapy JO - Cancer Sci VL - 109 UR - https://doi.org/10.1111/cas.13663 DO - 10.1111/cas.13663 ID - Murata2018 ER - TY - JOUR AU - Feng, R. AU - Zhao, H. AU - Xu, J. AU - Shen, C. PY - 2020 DA - 2020// TI - CD47: the next checkpoint target for cancer immunotherapy JO - Crit Rev Oncol Hematol VL - 152 UR - https://doi.org/10.1016/j.critrevonc.2020.103014 DO - 10.1016/j.critrevonc.2020.103014 ID - Feng2020 ER - TY - JOUR AU - Sikic, B. I. AU - Lakhani, N. J. AU - Patnaik, A. PY - 2018 DA - 2018// TI - A first-in-class, first-in-human phase 1 pharmacokinetic (PK) and pharmacodynamic (PD) study of Hu5F9-G4, an anti-CD47 monoclonal antibody (mAb), in patients with advanced solid tumors JO - J Clin Oncol VL - 36 UR - https://doi.org/10.1200/JCO.2018.36.15_suppl.3002 DO - 10.1200/JCO.2018.36.15_suppl.3002 ID - Sikic2018 ER - TY - JOUR AU - Advani, R. AU - Bartlett, N. L. AU - Smith, S. M. PY - 2019 DA - 2019// TI - The first-in-class ant-CD47 Antibody HU5F9-G4 + rituximab induces durable responses in relapsed/refractory DLBCL and indolent lymphoma: interim phase 1b/2 results JO - Hematol Oncol VL - 37 UR - https://doi.org/10.1002/hon.57_2629 DO - 10.1002/hon.57_2629 ID - Advani2019 ER - TY - JOUR AU - Advani, R. H. AU - Flinn, I. AU - Popplewell, L. PY - 2018 DA - 2018// TI - Activity and tolerabilty of the first-in-class anti-CD47 antibody Hu5F9-G4 with rituximab tolerated in relapsed/refractory non-Hodgkin lymphoma: initial phase 1b/2 results JO - J Clin Oncol VL - 36 UR - https://doi.org/10.1200/JCO.2018.36.15_suppl.7504 DO - 10.1200/JCO.2018.36.15_suppl.7504 ID - Advani2018 ER - TY - JOUR AU - Chow, L. Q. M. AU - Gainor, J. F. AU - Lakhani, N. J. PY - 2020 DA - 2020// TI - A phase I study of ALX148, a CD47 blocker, in combination with standard anticancer antibodies and chemotherapy regimens in patients with advanced malignancy JO - J Clin Oncol VL - 38 UR - https://doi.org/10.1200/JCO.2020.38.15_suppl.3056 DO - 10.1200/JCO.2020.38.15_suppl.3056 ID - Chow2020 ER - TY - JOUR AU - Lakhani, N. J. AU - LoRusso, P. AU - Hafez, N. PY - 2018 DA - 2018// TI - A phase 1 study of ALX148, a CD47 blocker, alone and in combination with established anticancer antibodies in patients with advanced malignancy and non-Hodgkin lymphoma JO - J Clin Oncol VL - 36 UR - https://doi.org/10.1200/JCO.2018.36.15_suppl.3068 DO - 10.1200/JCO.2018.36.15_suppl.3068 ID - Lakhani2018 ER - TY - JOUR AU - Patel, K. AU - Maris, M. B. AU - Cheson, B. D. PY - 2020 DA - 2020// TI - Ongoing, first-in-human, phase I dose escalation study of the investigational CD47-blocker TTI-622 in patients with advanced relapsed or refractory lymphoma JO - J Clin Oncol VL - 38 UR - https://doi.org/10.1200/JCO.2020.38.15_suppl.3030 DO - 10.1200/JCO.2020.38.15_suppl.3030 ID - Patel2020 ER - TY - JOUR AU - Cabrales, P. PY - 2019 DA - 2019// TI - RRx-001 acts as a dual small molecule checkpoint inhibitor by downregulating CD47 on cancer cells and SIRP-alpha on monocytes/macrophages JO - Transl Oncol VL - 12 UR - https://doi.org/10.1016/j.tranon.2018.12.001 DO - 10.1016/j.tranon.2018.12.001 ID - Cabrales2019 ER - TY - JOUR AU - Carter, C. AU - Caroen, S. AU - Oronsky, B. AU - Quinn, M. F. AU - Williams, J. AU - Brzezniak, C. E. PY - 2020 DA - 2020// TI - Phase I pilot study of RRx-001 + nivolumab in patients with traditionally non-checkpoint inhibitor-responsive cancers (PRIMETIME) JO - J Clin Oncol VL - 38 UR - https://doi.org/10.1200/JCO.2020.38.15_suppl.e15119 DO - 10.1200/JCO.2020.38.15_suppl.e15119 ID - Carter2020 ER - TY - JOUR AU - Ley, K. PY - 2017 DA - 2017// TI - M1 means kill; M2 means heal JO - J Immunol VL - 199 UR - https://doi.org/10.4049/jimmunol.1701135 DO - 10.4049/jimmunol.1701135 ID - Ley2017 ER - TY - JOUR AU - Ostuni, R. AU - Kratochvill, F. AU - Murray, P. J. AU - Natoli, G. PY - 2015 DA - 2015// TI - Macrophages and cancer: from mechanisms to therapeutic implications JO - Trends Immunol VL - 36 UR - https://doi.org/10.1016/j.it.2015.02.004 DO - 10.1016/j.it.2015.02.004 ID - Ostuni2015 ER - TY - JOUR AU - Chen, Y. AU - Song, Y. AU - Du, W. AU - Gong, L. AU - Chang, H. AU - Zou, Z. PY - 2019 DA - 2019// TI - Tumor-associated macrophages: an accomplice in solid tumor progression JO - J Biomed Sci VL - 26 UR - https://doi.org/10.1186/s12929-019-0568-z DO - 10.1186/s12929-019-0568-z ID - Chen2019 ER - TY - JOUR AU - Beltraminelli, T. AU - Palma, M. PY - 2020 DA - 2020// TI - Biology and therapeutic targeting of tumour-associated macrophages JO - J Pathol VL - 250 UR - https://doi.org/10.1002/path.5403 DO - 10.1002/path.5403 ID - Beltraminelli2020 ER - TY - JOUR AU - Cannarile, M. A. AU - Weisser, M. AU - Jacob, W. AU - Jegg, A. M. AU - Ries, C. H. AU - Ruttinger, D. PY - 2017 DA - 2017// TI - Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy JO - J Immunother Cancer VL - 5 UR - https://doi.org/10.1186/s40425-017-0257-y DO - 10.1186/s40425-017-0257-y ID - Cannarile2017 ER - TY - JOUR AU - Dammeijer, F. AU - Lievense, L. A. AU - Kaijen-Lambers, M. E. PY - 2017 DA - 2017// TI - Depletion of tumor-associated macrophages with a CSF-1R kinase inhibitor enhances antitumor immunity and survival induced by DC immunotherapy JO - Cancer Immunol Res VL - 5 UR - https://doi.org/10.1158/2326-6066.CIR-16-0309 DO - 10.1158/2326-6066.CIR-16-0309 ID - Dammeijer2017 ER - TY - JOUR AU - Cannarile, M. A. AU - Weisser, M. AU - Jacob, W. AU - Jegg, A. -. M. AU - Ries, C. H. AU - Rüttinger, D. PY - 2017 DA - 2017// TI - Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy JO - J Immunother Cancer VL - 5 UR - https://doi.org/10.1186/s40425-017-0257-y DO - 10.1186/s40425-017-0257-y ID - Cannarile2017 ER - TY - JOUR AU - Calvo, A. AU - Joensuu, H. AU - Sebastian, M. PY - 2018 DA - 2018// TI - Phase Ib/II study of lacnotuzumab (MCS110) combined with spartalizumab (PDR001) in patients (pts) with advanced tumors JO - J Clin Oncol VL - 36 UR - https://doi.org/10.1200/JCO.2018.36.15_suppl.3014 DO - 10.1200/JCO.2018.36.15_suppl.3014 ID - Calvo2018 ER - TY - JOUR AU - Autio, K. A. AU - Klebanoff, C. A. AU - Schaer, D. PY - 2019 DA - 2019// TI - Phase 1 study of LY3022855, a colony-stimulating factor-1 receptor (CSF-1R) inhibitor, in patients with metastatic breast cancer (MBC) or metastatic castration-resistant prostate cancer (MCRPC) JO - J Clin Oncol VL - 37 UR - https://doi.org/10.1200/JCO.2019.37.15_suppl.2548 DO - 10.1200/JCO.2019.37.15_suppl.2548 ID - Autio2019 ER - TY - JOUR AU - Autio, K. A. AU - Klebanoff, C. A. AU - Schaer, D. PY - 2020 DA - 2020// TI - Immunomodulatory activity of a colony-stimulating factor-1 receptor inhibitor in patients with advanced refractory breast or prostate cancer: a phase I study JO - Clin Cancer Res VL - 26 UR - https://doi.org/10.1158/1078-0432.CCR-20-0855 DO - 10.1158/1078-0432.CCR-20-0855 ID - Autio2020 ER - TY - STD TI - Azad N, Rasco D, Sharma S, et al. Abstract CT149: SNDX-6352-0502-A phase 1, open-label, dose escalation trial to investigate the safety, tolerability, pharmacokinetics and pharmacodynamic activity of SNDX-6352 monotherapy in patients with unresectable, recurrent, locally-advanced, or metastatic solid tumors. In: AACR; 2020. ID - ref101 ER - TY - JOUR AU - Gomez-Roca, C. A. AU - Italiano, A. AU - Tourneau, C. PY - 2019 DA - 2019// TI - Phase I study of emactuzumab single agent or in combination with paclitaxel in patients with advanced/metastatic solid tumors reveals depletion of immunosuppressive M2-like macrophages JO - Ann Oncol VL - 30 UR - https://doi.org/10.1093/annonc/mdz163 DO - 10.1093/annonc/mdz163 ID - Gomez-Roca2019 ER - TY - JOUR AU - Wesolowski, R. AU - Sharma, N. AU - Reebel, L. PY - 2019 DA - 2019// TI - Phase Ib study of the combination of pexidartinib (PLX3397), a CSF-1R inhibitor, and paclitaxel in patients with advanced solid tumors JO - Therapeutic Adv Med Oncol VL - 11 ID - Wesolowski2019 ER - TY - JOUR AU - Cassier, P. A. AU - Garin, G. AU - Eberst, L. PY - 2019 DA - 2019// TI - MEDIPLEX: a phase 1 study of durvalumab (D) combined with pexidartinib (P) in patients (pts) with advanced pancreatic ductal adenocarcinoma (PDAC) and colorectal cancer (CRC) JO - J Clin Oncol VL - 37 UR - https://doi.org/10.1200/JCO.2019.37.15_suppl.2579 DO - 10.1200/JCO.2019.37.15_suppl.2579 ID - Cassier2019 ER - TY - JOUR AU - Zhao, P. AU - Li, L. AU - Jiang, X. AU - Li, Q. PY - 2019 DA - 2019// TI - Mismatch repair deficiency/microsatellite instability-high as a predictor for anti-PD-1/PD-L1 immunotherapy efficacy JO - J Hematol Oncol VL - 12 UR - https://doi.org/10.1186/s13045-019-0738-1 DO - 10.1186/s13045-019-0738-1 ID - Zhao2019 ER - TY - JOUR AU - Lee, J. -. H. AU - Chen, T. W. W. AU - Hsu, C. -. H. PY - 2020 DA - 2020// TI - A phase I study of pexidartinib, a colony-stimulating factor 1 receptor inhibitor, in Asian patients with advanced solid tumors JO - Invest New Drug. VL - 38 UR - https://doi.org/10.1007/s10637-019-00745-z DO - 10.1007/s10637-019-00745-z ID - Lee2020 ER - TY - JOUR AU - Dinarello, C. A. PY - 2018 DA - 2018// TI - Overview of the IL-1 family in innate inflammation and acquired immunity JO - Immunol Rev VL - 281 UR - https://doi.org/10.1111/imr.12621 DO - 10.1111/imr.12621 ID - Dinarello2018 ER - TY - JOUR AU - Garlanda, C. AU - Dinarello, C. A. AU - Mantovani, A. PY - 2013 DA - 2013// TI - The interleukin-1 family: back to the future JO - Immunity VL - 39 UR - https://doi.org/10.1016/j.immuni.2013.11.010 DO - 10.1016/j.immuni.2013.11.010 ID - Garlanda2013 ER - TY - JOUR AU - Boraschi, D. AU - Italiani, P. AU - Weil, S. AU - Martin, M. U. PY - 2018 DA - 2018// TI - The family of the interleukin-1 receptors JO - Immunol Rev VL - 281 UR - https://doi.org/10.1111/imr.12606 DO - 10.1111/imr.12606 ID - Boraschi2018 ER - TY - JOUR AU - Xia, A. AU - Zhang, Y. AU - Xu, J. AU - Yin, T. AU - Lu, X. J. PY - 2019 DA - 2019// TI - T cell dysfunction in cancer immunity and immunotherapy JO - Front Immunol VL - 10 UR - https://doi.org/10.3389/fimmu.2019.01719 DO - 10.3389/fimmu.2019.01719 ID - Xia2019 ER - TY - JOUR AU - Litmanovich, A. AU - Khazim, K. AU - Cohen, I. PY - 2018 DA - 2018// TI - The role of interleukin-1 in the pathogenesis of cancer and its potential as a therapeutic target in clinical practice JO - Oncol Ther VL - 6 UR - https://doi.org/10.1007/s40487-018-0089-z DO - 10.1007/s40487-018-0089-z ID - Litmanovich2018 ER - TY - JOUR AU - Mantovani, A. AU - Barajon, I. AU - Garlanda, C. PY - 2018 DA - 2018// TI - IL-1 and IL-1 regulatory pathways in cancer progression and therapy JO - Immunol Rev VL - 281 UR - https://doi.org/10.1111/imr.12614 DO - 10.1111/imr.12614 ID - Mantovani2018 ER - TY - JOUR AU - Lewis, A. M. AU - Varghese, S. AU - Xu, H. AU - Alexander, H. R. PY - 2006 DA - 2006// TI - Interleukin-1 and cancer progression: the emerging role of interleukin-1 receptor antagonist as a novel therapeutic agent in cancer treatment JO - J Transl Med VL - 4 UR - https://doi.org/10.1186/1479-5876-4-48 DO - 10.1186/1479-5876-4-48 ID - Lewis2006 ER - TY - JOUR AU - Awada, A. AU - Eskens, F. AU - Robbrecht, D. PY - 2019 DA - 2019// TI - Results from a first-in-man, open label, safety and tolerability trial of CAN04 (nidanilimab), a fully humanized monoclonal antibody against the novel antitumor target, IL1RAP, in patients with solid tumor malignancies JO - J Clin Oncol VL - 37 UR - https://doi.org/10.1200/JCO.2019.37.15_suppl.2504 DO - 10.1200/JCO.2019.37.15_suppl.2504 ID - Awada2019 ER - TY - JOUR AU - Alfaro, C. AU - Sanmamed, M. F. AU - Rodríguez-Ruiz, M. E. PY - 2017 DA - 2017// TI - Interleukin-8 in cancer pathogenesis, treatment and follow-up JO - Cancer Treat Rev VL - 60 UR - https://doi.org/10.1016/j.ctrv.2017.08.004 DO - 10.1016/j.ctrv.2017.08.004 ID - Alfaro2017 ER - TY - JOUR AU - David, J. M. AU - Dominguez, C. AU - Hamilton, D. H. AU - Palena, C. PY - 2016 DA - 2016// TI - The IL-8/IL-8R axis: a double agent in tumor immune resistance JO - Vaccines (Basel). VL - 4 UR - https://doi.org/10.3390/vaccines4030022 DO - 10.3390/vaccines4030022 ID - David2016 ER - TY - JOUR AU - Bakouny, Z. AU - Choueiri, T. K. PY - 2020 DA - 2020// TI - IL-8 and cancer prognosis on immunotherapy JO - Nat Med VL - 26 UR - https://doi.org/10.1038/s41591-020-0873-9 DO - 10.1038/s41591-020-0873-9 ID - Bakouny2020 ER - TY - JOUR AU - Collins, J. M. AU - Heery, C. R. AU - Donahue, R. N. PY - 2018 DA - 2018// TI - Phase I trial of BMS-986253, an anti-IL-8 monoclonal antibody, in patients with metastatic or unresectable solid tumors JO - J Clin Oncol VL - 36 UR - https://doi.org/10.1200/JCO.2018.36.15_suppl.3091 DO - 10.1200/JCO.2018.36.15_suppl.3091 ID - Collins2018 ER - TY - JOUR AU - Bilusic, M. AU - Heery, C. R. AU - Collins, J. M. PY - 2019 DA - 2019// TI - Phase I trial of HuMax-IL8 (BMS-986253), an anti-IL-8 monoclonal antibody, in patients with metastatic or unresectable solid tumors JO - J Immunother Cancer VL - 7 UR - https://doi.org/10.1186/s40425-019-0706-x DO - 10.1186/s40425-019-0706-x ID - Bilusic2019 ER - TY - JOUR AU - Koncina, E. AU - Roth, L. AU - Gonthier, B. AU - Bagnard, D. PY - 2007 DA - 2007// TI - Role of semaphorins during axon growth and guidance JO - Adv Exp Med Biol VL - 621 UR - https://doi.org/10.1007/978-0-387-76715-4_4 DO - 10.1007/978-0-387-76715-4_4 ID - Koncina2007 ER - TY - JOUR AU - Chen, L. H. AU - Cuang, E. Y. PY - 2019 DA - 2019// TI - Importance of semaphorins in cancer immunity JO - Transl Lung Cancer Res VL - 8 UR - https://doi.org/10.21037/tlcr.2019.12.22 DO - 10.21037/tlcr.2019.12.22 ID - Chen2019 ER - TY - JOUR AU - Evans, E. E. AU - Jonason, A. S. AU - Bussler, H. PY - 2015 DA - 2015// TI - Antibody blockade of semaphorin 4D promotes immune infiltration into tumor and enhances response to other immunomodulatory therapies JO - Cancer Immunol Res VL - 3 UR - https://doi.org/10.1158/2326-6066.CIR-14-0171 DO - 10.1158/2326-6066.CIR-14-0171 ID - Evans2015 ER - TY - JOUR AU - McClellan, J. L. AU - Davis, J. M. AU - Steiner, J. L. PY - 2012 DA - 2012// TI - Linking tumor-associated macrophages, inflammation, and intestinal tumorigenesis: role of MCP-1 JO - Am J Physiol Gastrointest Liver Physiol VL - 303 UR - https://doi.org/10.1152/ajpgi.00252.2012 DO - 10.1152/ajpgi.00252.2012 ID - McClellan2012 ER - TY - JOUR AU - Shafique, M. R. AU - Fisher, T. L. AU - Evans, E. E. PY - 2020 DA - 2020// TI - Interim subgroup analysis for response by PD-L1 status of CLASSICAL-Lung, a phase Ib/II study of pepinemab (VX15/2503) in combination with avelumab in advanced NSCLC JO - J Clin Oncol VL - 38 UR - https://doi.org/10.1200/JCO.2020.38.15_suppl.3011 DO - 10.1200/JCO.2020.38.15_suppl.3011 ID - Shafique2020 ER - TY - JOUR AU - Augustin, H. G. AU - Koh, G. Y. AU - Thurston, G. AU - Alitalo, K. PY - 2009 DA - 2009// TI - Control of vascular morphogenesis and homeostasis through the angiopoietin-Tie system JO - Nat Rev Mol Cell Biol VL - 10 UR - https://doi.org/10.1038/nrm2639 DO - 10.1038/nrm2639 ID - Augustin2009 ER - TY - JOUR AU - Scholz, A. AU - Plate, K. H. AU - Reiss, Y. PY - 2015 DA - 2015// TI - Angiopoietin-2: a multifaceted cytokine that functions in both angiogenesis and inflammation JO - Ann N Y Acad Sci VL - 1347 UR - https://doi.org/10.1111/nyas.12726 DO - 10.1111/nyas.12726 ID - Scholz2015 ER - TY - JOUR AU - Scholz, A. AU - Lang, V. AU - Henschler, R. PY - 2011 DA - 2011// TI - Angiopoietin-2 promotes myeloid cell infiltration in a beta(2)-integrin-dependent manner JO - Blood VL - 118 UR - https://doi.org/10.1182/blood-2011-03-343293 DO - 10.1182/blood-2011-03-343293 ID - Scholz2011 ER - TY - JOUR AU - Wu, X. AU - Giobbie-Hurder, A. AU - Liao, X. PY - 2017 DA - 2017// TI - Angiopoietin-2 as a biomarker and target for immune checkpoint therapy JO - Cancer Immunol Res VL - 5 UR - https://doi.org/10.1158/2326-6066.CIR-16-0206 DO - 10.1158/2326-6066.CIR-16-0206 ID - Wu2017 ER - TY - JOUR AU - Rahma, O. E. AU - Cleary, J. M. AU - Schlechter, B. L. PY - 2019 DA - 2019// TI - Phase Ib study of pembrolizumab and trebananib (angiopoietin-2 inhibitor [Ang-2]): preliminary analysis of the colorectal cancer (CRC) cohort JO - J Clin Oncol VL - 37 UR - https://doi.org/10.1200/JCO.2019.37.15_suppl.e14160 DO - 10.1200/JCO.2019.37.15_suppl.e14160 ID - Rahma2019 ER - TY - JOUR AU - Le, D. T. AU - Uram, J. N. AU - Wang, H. PY - 2015 DA - 2015// TI - PD-1 blockade in tumors with mismatch-repair deficiency JO - N Engl J Med VL - 372 UR - https://doi.org/10.1056/NEJMoa1500596 DO - 10.1056/NEJMoa1500596 ID - Le2015 ER - TY - JOUR AU - Kzhyshkowska, J. AU - Gratchev, A. AU - Goerdt, S. PY - 2006 DA - 2006// TI - Stabilin-1, a homeostatic scavenger receptor with multiple functions JO - J Cell Mol Med VL - 10 UR - https://doi.org/10.1111/j.1582-4934.2006.tb00425.x DO - 10.1111/j.1582-4934.2006.tb00425.x ID - Kzhyshkowska2006 ER - TY - JOUR AU - Viitala, M. AU - Virtakoivu, R. AU - Tadayon, S. AU - Rannikko, J. AU - Jalkanen, S. AU - Hollmen, M. PY - 2019 DA - 2019// TI - Immunotherapeutic blockade of macrophage clever-1 reactivates the CD8(+) T-cell response against immunosuppressive tumors JO - Clin Cancer Res VL - 25 UR - https://doi.org/10.1158/1078-0432.CCR-18-3016 DO - 10.1158/1078-0432.CCR-18-3016 ID - Viitala2019 ER - TY - JOUR AU - Bono, P. AU - Virtakoivu, R. AU - Vaura, F. PY - 2020 DA - 2020// TI - Immune activation in first-in-human anti-macrophage antibody (anti-Clever-1 mAb; FP-1305) phase I/II MATINS trial: part I dose-escalation, safety, and efficacy results JO - J Clin Oncol VL - 38 UR - https://doi.org/10.1200/JCO.2020.38.15_suppl.3097 DO - 10.1200/JCO.2020.38.15_suppl.3097 ID - Bono2020 ER - TY - JOUR AU - Lemke, G. PY - 2013 DA - 2013// TI - Biology of the TAM receptors JO - Cold Spring Harb Perspect Biol VL - 5 UR - https://doi.org/10.1101/cshperspect.a009076 DO - 10.1101/cshperspect.a009076 ID - Lemke2013 ER - TY - JOUR AU - Zhu, C. AU - Wei, Y. AU - Wei, X. PY - 2019 DA - 2019// TI - AXL receptor tyrosine kinase as a promising anti-cancer approach: functions, molecular mechanisms and clinical applications JO - Mol Cancer VL - 18 UR - https://doi.org/10.1186/s12943-019-1090-3 DO - 10.1186/s12943-019-1090-3 ID - Zhu2019 ER - TY - JOUR AU - Aguilera, T. A. AU - Giaccia, A. J. PY - 2017 DA - 2017// TI - Molecular pathways: oncologic pathways and their role in T-cell exclusion and immune evasion—a new role for the AXL receptor tyrosine kinase JO - Clin Cancer Res VL - 23 UR - https://doi.org/10.1158/1078-0432.CCR-17-0189 DO - 10.1158/1078-0432.CCR-17-0189 ID - Aguilera2017 ER - TY - JOUR AU - Ameratunga, M. AU - Harvey, R. D. AU - Mau-Sørensen, M. PY - 2019 DA - 2019// TI - First-in-human, dose-escalation, phase (ph) I trial to evaluate safety of anti-Axl antibody-drug conjugate (ADC) enapotamab vedotin (EnaV) in solid tumors JO - J Clin Oncol VL - 37 UR - https://doi.org/10.1200/JCO.2019.37.15_suppl.2525 DO - 10.1200/JCO.2019.37.15_suppl.2525 ID - Ameratunga2019 ER - TY - JOUR AU - Dayoub, A. S. AU - Brekken, R. A. PY - 2020 DA - 2020// TI - TIMs, TAMs, and PS-antibody targeting: implications for cancer immunotherapy JO - Cell Commun Signal VL - 18 UR - https://doi.org/10.1186/s12964-020-0521-5 DO - 10.1186/s12964-020-0521-5 ID - Dayoub2020 ER - TY - JOUR AU - Yin, Y. AU - Huang, X. AU - Lynn, K. D. AU - Thorpe, P. E. PY - 2013 DA - 2013// TI - Phosphatidylserine-targeting antibody induces M1 macrophage polarization and promotes myeloid-derived suppressor cell differentiation JO - Cancer Immunol Res VL - 1 UR - https://doi.org/10.1158/2326-6066.CIR-13-0073 DO - 10.1158/2326-6066.CIR-13-0073 ID - Yin2013 ER - TY - JOUR AU - Mokdad, A. A. AU - Zhu, H. AU - Beg, M. S. PY - 2019 DA - 2019// TI - Efficacy and safety of bavituximab in combination with sorafenib in advanced hepatocellular carcinoma: a single-arm, open-label, phase II clinical trial JO - Target Oncol VL - 14 UR - https://doi.org/10.1007/s11523-019-00663-3 DO - 10.1007/s11523-019-00663-3 ID - Mokdad2019 ER -